drugset / Trial / NCT04920786
Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects
RandomizedSequentialTriple-blindTreatment
Summary
This is a single dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TB006, a monoclonal antibody that will be studied as a disease modifying treatment for Alzheimer's disease.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2022-05-03
- Completion
- 2022-05-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TB006 | Monoclonal antibody | 70 mg | Intravenous |
| Subject | TB006 | Monoclonal antibody | 5000 mg | Intravenous |